Adhesive-based medical devices manufacturer Chemence Medical has secured approval from the US Food and Drug Administration (FDA) for its Exofin, a new topical skin adhesive for wound closure.
The new polymerizing 2-octyl cyanoacrylate topical adhesive is claimed to be the higher viscosity formulation.
Chemence Medical president Jeff Roberson said: "After spending more than two years observing and talking to healthcare professionals throughout all departments of hospitals across America, it became clear that no single topical adhesive had all of the attributes that mattered most.
"Chemence Medical has combined your feedback with the very best R&D department in the USA and created a topical skin adhesive that delivers on all of the requirements you asked for."
The new topical skin adhesive is available in two sizes, each with its own unique and advanced applicator.
Exofin High Viscosity Tissue Adhesive features 1ml tube fill that provides users with the highest volume per device. Its flexible applicator with a transparent tip allows user to see the adhesive prior to expression and create a solid seal on skin, including uneven surfaces.
Featruing .5ml tube fill, Exofin Micro is suitable for small trauma induced injuries and single port incisions.
It uses a clear silicone tip for precision applications, and provides the same high viscosity formulation as the larger sized Exofin.
Roberson further added: "Exofin delivers the speed, strength and innovation customers have asked for while being easy to use."
Chemence Medical produces and markets adhesive-based medical devices, which are protected by a portfolio of patents covering various aspects of cyanoacrylate and mechanical technologies.
Image: Chemence Medical has unveiled Exofin High Viscosity Tissue Adhesive and Exofin Micro. Photo: courtesy of Business Wire.